Literature DB >> 11740816

Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

R J D'Amato1, S Lentzsch, K C Anderson, M S Rogers.   

Abstract

We have explored the mechanism of the antiangiogenic effects of thalidomide by structure-activity studies. These investigations revealed that angiogenesis inhibition correlates with teratogenicity but not with tumor necrosis factor-alpha (TFA-alpha) inhibition. Additionally, one analog of thalidomide, 3-aminothalidomide, exhibited an unusual capacity to directly inhibit myeloma cell proliferation. This activity did not correlate with TNF-alpha inhibition. Thus 3-aminothalidomide was found to inhibit multiple myeloma through effects on both the tumor and vascular compartment. The effects of an inhibitor of both the tumor and vascular compartments of a tumor on tumor growth may be synergistic. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740816     DOI: 10.1053/sonc.2001.28601

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

Review 1.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

2.  A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.

Authors:  Taimur Sher; Sikander Ailawadhi; Kena C Miller; Debbie Manfredi; Margaret Wood; Wei Tan; Gregory Wilding; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri; Fredrick Hong; Raman Sood; Saif Soniwala; William Lawrence; Saad Jamshed; Aisha Masood; Daniel Iancu; Kelvin Lee; Asher Chanan-Khan
Journal:  Br J Haematol       Date:  2011-05-09       Impact factor: 6.998

Review 3.  New immunomodulatory drugs in myeloma.

Authors:  Martha Q Lacy
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

4.  Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.

Authors:  Ken-Ichi Kitazoe; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Takeshi Harada; Ayako Nakano; Kyoko Takeuchi; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

Review 5.  Thalidomide-a notorious sedative to a wonder anticancer drug.

Authors:  Shuang Zhou; Fengfei Wang; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies.

Authors:  Josh W DiGiacomo; Daniele M Gilkes
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

7.  Targeting the tumor microenvironment: focus on angiogenesis.

Authors:  Fengjuan Fan; Alexander Schimming; Dirk Jaeger; Klaus Podar
Journal:  J Oncol       Date:  2011-08-24       Impact factor: 4.375

Review 8.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927

Review 9.  Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement.

Authors:  Patrizia Tosi
Journal:  Scientifica (Cairo)       Date:  2013-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.